|
Chronic lymphocytic leukaemia refractory
|
0.010 |
Biomarker
|
disease |
BEFREE |
At the present time, GS-1101, which reversibly inhibits PI3Kδ, and ibrutinib (PCI-32765), an irreversible inhibitor of Bruton tyrosine kinase, have generated the most promising early results in clinical trials including predominately refractory CLL where durable disease control has been observed.
|
22715122 |
2012 |
|
Nephroblastoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
For example, the IBtK protein and the SH2 domain-containing protein were present in siRNA(WT1) conditions, while the platelet-derived growth factor receptor α (PDGFRA) and Rho guanine nucleotide exchange factor 1 (Rho-GEF 1) were expressed in siRNA(neg).
|
24503937 |
2014 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is effective in chronic lymphocytic leukemia (CLL).
|
24869598 |
2014 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
In preclinical studies, ibrutinib potently bound to Btk, inhibited BCR signaling, and decreased tumor cell proliferation and survival in many B-cell malignancy models.
|
25669675 |
2015 |
|
Diffuse Large B-Cell Lymphoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Deletions of CDKN2A/B (28%) and IBTK (23%) were frequent events in relapsed DLBCLs.
|
27276707 |
2016 |
|
B-Cell Lymphomas
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Ibrutinib (Imbruvica<sup>®</sup>) is an oral irreversible inhibitor of Bruton's tyrosine kinase, a B-cell receptor (BCR) signalling kinase expressed by various haematopoietic cells, B-cell lymphomas and leukaemias.
|
28105602 |
2017 |
|
leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Ibrutinib (Imbruvica<sup>®</sup>) is an oral irreversible inhibitor of Bruton's tyrosine kinase, a B-cell receptor (BCR) signalling kinase expressed by various haematopoietic cells, B-cell lymphomas and leukaemias.
|
28105602 |
2017 |
|
Lymphoproliferative Disorders
|
0.020 |
Biomarker
|
group |
BEFREE |
Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (Btk) that has proven to be an effective therapeutic agent for multiple B-cell-mediated lymphoproliferative disorders.
|
28182323 |
2017 |
|
Neoplasms
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Primary and acquired resistance to ibrutinib, an oral covalent inhibitor of Bruton tyrosine kinase, were investigated to elucidate the mechanisms underlying ibrutinib resistance and to identify drug treatments to overcome resistance.<b>Results:</b> The PDXs maintained the same biological, histopathologic, and immunophenotypical features, retained similar genetic mutations, and produced comparable drug responses with the original patient tumors.
|
28348046 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ibrutinib, an oral inhibitor of Bruton's tyrosine kinase (BTK), at a once-daily dose of 420 mg achieved BTK active-site occupancy in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) that was maintained at 24 hours.
|
28373262 |
2017 |
|
Small Lymphocytic Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Ibrutinib, an oral inhibitor of Bruton's tyrosine kinase (BTK), at a once-daily dose of 420 mg achieved BTK active-site occupancy in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) that was maintained at 24 hours.
|
28373262 |
2017 |
|
Nonalcoholic Steatohepatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Function of inhibitor of Bruton's tyrosine kinase isoform α (IBTKα) in nonalcoholic steatohepatitis links autophagy and the unfolded protein response.
|
28710282 |
2017 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Ibrutinib, an irreversible inhibitor of Bruton tyrosine kinase (BTK), is a novel drug that has shown significant efficacy and survival benefit for treatment of various B-cell malignancies.
|
28760303 |
2017 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Ibrutinib, the first-in-class inhibitor of Bruton tyrosine kinase, and idelalisib, the first-in-class inhibitor of phosphatidylinositol 3-kinase <b>δ</b>, have recently been approved for the treatment of several indolent B-cell malignancies.
|
28775119 |
2017 |
|
Diffuse Large B-Cell Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
<b/> In this issue Grommes and colleagues elegantly show that the irreversible inhibitor of Bruton tyrosine kinase, ibrutinib, promotes a high proportion of durable responses in primary central nervous system lymphoma, a type of diffuse large B-cell lymphoma (DLBCL), and also in secondary DLBCL relapsing to the central nervous system.
|
28864640 |
2017 |
|
Primary central nervous system lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b/> In this issue Grommes and colleagues elegantly show that the irreversible inhibitor of Bruton tyrosine kinase, ibrutinib, promotes a high proportion of durable responses in primary central nervous system lymphoma, a type of diffuse large B-cell lymphoma (DLBCL), and also in secondary DLBCL relapsing to the central nervous system.
|
28864640 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ibrutinib, a covalent inhibitor of Bruton Tyrosine Kinase (BTK), is approved for treatment of patients with relapsed/refractory or treatment-naïve chronic lymphocytic leukemia (CLL).
|
28972595 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of inhibitor of bruton's tyrosine kinase gene is progressively up regulated in the clinical course of chronic lymphocytic leukaemia conferring resistance to apoptosis.
|
29317636 |
2018 |
|
Multiple Myeloma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Ibrutinib (also referred to as PCI-32765), an inhibitor of Bruton's tyrosine kinase, while its effects on multiple myeloma have not been well described.
|
29320977 |
2018 |
|
Brain Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
We used a novel inhibitor of Bruton's tyrosine kinase (BTK), BI-BTK-1, to target both macrophage and B cell function in the MRL-lpr/lpr murine model of SLE, and examined the effect of treatment on skin and brain disease.
|
29370834 |
2018 |
|
Lymphoproliferative Disorders
|
0.020 |
Biomarker
|
group |
BEFREE |
Atrial fibrillation is a side effect of ibrutinib, an irreversible inhibitor of Bruton tyrosine kinase used for treatment of B-cell lymphoproliferative disorders.
|
29475534 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ibrutinib is an oral irreversible inhibitor of Bruton's tyrosine kinase, indicated for the treatment of chronic lymphocytic leukaemia.
|
29891001 |
2018 |
|
Mantle cell lymphoma refractory
|
0.010 |
Biomarker
|
disease |
BEFREE |
Targeted agents such as ibrutinib, an inhibitor of Bruton's tyrosine kinase, which has been approved only in the relapsed setting, can be used to treat patients with relapsed or refractory mantle cell lymphoma.
|
29907126 |
2018 |
|
Mantle cell lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
This first-in-class inhibitor of Bruton's tyrosine kinase has become a standard treatment for patients with CLL and MCL.
|
30061088 |
2018 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase approved for the treatment of B-cell malignancies.
|
30090839 |
2018 |